Sunday, May 31, 2015

CLDX: Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met

New alert via PocketInfo for CLDX:

Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met

Press Releases: http://ir.celldextherapeutics.com/releases.cfm
SEC Filings: http://ir.celldextherapeutics.com/sec.cfm
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8

No comments:

Post a Comment